Pancreatic Cancer Game Changer? “If An 81-year-old Is Not A Candidate For Chemo, Now I Have An Option”

New data from the phase 3 RASolute 302 trial (NCT06625320)—reported in a press release from Revolution Medicines—may signal more than a promising new drug. It may mark a shift in how pancreatic cancer is treated.

According to Dr. Nicholas Hornstein of Northwell’s Lenox Hill Hospital, “If I have an 81-year-old that walks into my clinic and doesn’t look like they’re a candidate for chemotherapy, now I have an option that isn’t chemo.”

In the randomized phase 3 study, patients with previously treated metastatic pancreatic cancer were assigned to the KRAS inhibitor drug daraxonrasib or the investigator’s choice of standard chemotherapy. Median overall survival more than doubled—13.2 months versus 6.7 months—a result drawing rare attention in a setting where outcomes are typically measured in months

Dr. Anna Berkenblit, MMSc, Chief Scientific and Medical Officer at The Pancreatic Cancer Action Network (PanCAN), called the findings “unprecedented, ” and noted that survival was “approximately doubled with a once-daily pill” in a group of patients with limited options.

The reaction in the field has been immediate.  “This press release was so profound that you have medical oncologists like myself basically jumping up and down,” added Dr. Hornstein.

What This Means for Pancreatic Cancer Care

For decades, pancreatic cancer has been defined by a central paradox: its biology is well understood, but largely untreatable at its core.

At the center is the KRAS gene, which is mutated in roughly 90% of pancreatic cancers and drives the disease. Yet despite its importance, KRAS has long resisted drug development.

According to the Journal of Clinical Medicine, “Kirsten rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in numerous cancer types, such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).”

“It has a moniker—the ‘undruggable gene,’” said Dr. Hornstein.

What makes this moment different is not just that a drug worked—it’s that it may work across the dominant biology of the disease. Earlier KRAS inhibitors have largely targeted specific mutations, such as G12C, which are uncommon in pancreatic cancer. A therapy that appears to target multiple KRAS mutations could expand treatment beyond a niche approach to one relevant to the majority of patients.

That shift—from understanding KRAS to potentially treating it at scale—is why these results are being interpreted as more than incremental progress.

A New Way to Target a Long-Elusive Pathway

KRAS has proven difficult to target in part because of its structure.  Most cancer drugs bind to a pocket on a protein, but KRAS lacks such a pocket.

“It’s a very smooth protein,” Dr. Hornstein said. “It doesn’t have places for drugs to grab onto.”

Daraxonrasib takes a different approach. Rather than binding in the traditional way, it acts as a “molecular glue,” binding KRAS to another protein and locking it into an inactive state.

“It basically ties them together so that other things can’t react,” he said.

This strategy could allow the drug to work across multiple KRAS mutations, potentially expanding its reach to a broader group of pancreatic cancer patients.

What This Means in Practice

If confirmed with full data and regulatory approval, daraxonrasib could change how clinicians approach the second-line setting.

Dr. Berkenblit said the implications are significant.   “The results from this study will change the standard of care if daraxonrasib is approved by the FDA when they review all the data,” she said.

Based on current data, the initial role would be in patients who have received prior chemotherapy. But the clinical impact may be most immediate among patients with limited tolerance for additional treatment.

Interest is already building in moving RAS-targeted therapies earlier.  “Ongoing trials are addressing both the frontline and the adjuvant setting,” Dr. Berkenblit said.

At the same time, key questions remain.  “With today’s press release, it’s a little too early to answer which patients to prioritize, since we haven’t seen all the data yet,” she added.

Side Effects and Real-World Use

Like most cancer treatments, daraxonrasib is not without side effects.

Reported toxicities include diarrhea and dermatologic reactions, which can be significant, with management strategies evolving.

“I don’t want to say minimal—toxicity is real,” Dr. Hornstein said. “But compared to chemotherapy, it seems a lot better.”

What Doctors Are Waiting For

Despite the enthusiasm, physicians are still seeking key data to guide their use.

“We will want to see additional details on all efficacy endpoints, including progression-free survival, as well as details on efficacy in subsets — in patients with tumors that have RAS G12 mutations, as well as those without a RAS mutation,” Dr. Berkenblit said.  “We will also want to see safety data to understand how to manage side effects of daraxonrasib.”

More detailed results—including progression-free survival, response rates, and subgroup analyses—are expected at upcoming meetings such as the ASCO Annual Meeting.

What Comes Next

If confirmed, these results are likely to shift how doctors think about treatment sequencing.

The immediate role is likely to be in a second-line setting. The next question is whether this approach moves earlier—into first-line or combination strategies.

Since KRAS mutations are common across cancers, the implications may extend beyond pancreatic cancer.

“I’m excited not just for pancreatic cancer patients,” said Dr. Hornstein, “but for cancer patients in general.”